HK1031825A1 - Cd154 blockade therapy for therapeutic protein inhibitor syndrome. - Google Patents

Cd154 blockade therapy for therapeutic protein inhibitor syndrome.

Info

Publication number
HK1031825A1
HK1031825A1 HK01101074A HK01101074A HK1031825A1 HK 1031825 A1 HK1031825 A1 HK 1031825A1 HK 01101074 A HK01101074 A HK 01101074A HK 01101074 A HK01101074 A HK 01101074A HK 1031825 A1 HK1031825 A1 HK 1031825A1
Authority
HK
Hong Kong
Prior art keywords
protein inhibitor
therapeutic protein
blockade therapy
inhibitor syndrome
exogenous protein
Prior art date
Application number
HK01101074A
Other languages
English (en)
Inventor
Burt Adelman
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of HK1031825A1 publication Critical patent/HK1031825A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK01101074A 1997-06-20 2001-02-14 Cd154 blockade therapy for therapeutic protein inhibitor syndrome. HK1031825A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20
PCT/US1998/012773 WO1998058672A1 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for therapeutic protein inhibitor syndrome

Publications (1)

Publication Number Publication Date
HK1031825A1 true HK1031825A1 (en) 2001-06-29

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01101074A HK1031825A1 (en) 1997-06-20 2001-02-14 Cd154 blockade therapy for therapeutic protein inhibitor syndrome.

Country Status (25)

Country Link
US (1) US20020119151A1 (is)
EP (1) EP1034001B1 (is)
JP (1) JP2002504910A (is)
KR (1) KR100567998B1 (is)
CN (2) CN1651071A (is)
AT (1) ATE272408T1 (is)
AU (1) AU733062B2 (is)
BG (1) BG64436B1 (is)
BR (1) BR9810755A (is)
CA (1) CA2294138A1 (is)
CZ (1) CZ295805B6 (is)
DE (1) DE69825473T2 (is)
EA (1) EA002512B1 (is)
EE (1) EE9900587A (is)
ES (1) ES2226152T3 (is)
HK (1) HK1031825A1 (is)
HU (1) HUP0002048A3 (is)
IL (1) IL133305A0 (is)
IS (1) IS2097B (is)
NO (1) NO996274L (is)
NZ (1) NZ502051A (is)
PT (1) PT1034001E (is)
SK (1) SK285962B6 (is)
TR (1) TR199903141T2 (is)
WO (1) WO1998058672A1 (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005236B1 (ru) * 1998-09-21 2004-12-30 ДЖИНЕТИКС ИНСТИТЬЮТ, эЛэЛСи Композиция для лечения и/или предупреждения нарушений, приводящих к аномальному кровотечению, и способ лечения таких нарушений (варианты)
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2408691A1 (en) 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
IES20030299A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
EP1639014B1 (en) * 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
JP4765039B2 (ja) 2003-11-04 2011-09-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃｄ４０抗原を発現する癌に対する治療方法。
MX2007001015A (es) 2004-07-26 2007-04-12 Biogen Idec Inc Anticuerpos anti-cd154.
WO2006017574A1 (en) * 2004-08-03 2006-02-16 Mayo Foundation For Medical Education And Research Improving treatments
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US9447156B2 (en) 2011-05-17 2016-09-20 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
KR100632846B1 (ko) * 1997-01-10 2006-10-16 바이오겐 아이덱 엠에이 인코포레이티드 치료를 위한 항ｃｄ40ｌ 화합물의 투여 방법

Also Published As

Publication number Publication date
EP1034001B1 (en) 2004-08-04
US20020119151A1 (en) 2002-08-29
KR100567998B1 (ko) 2006-04-07
DE69825473T2 (de) 2005-08-04
IS2097B (is) 2006-04-12
CN1651071A (zh) 2005-08-10
CA2294138A1 (en) 1998-12-30
BG64436B1 (en) 2005-02-28
AU8153698A (en) 1999-01-04
JP2002504910A (ja) 2002-02-12
SK285962B6 (sk) 2007-12-06
AU733062B2 (en) 2001-05-03
ATE272408T1 (de) 2004-08-15
NZ502051A (en) 2001-04-27
TR199903141T2 (xx) 2000-09-21
WO1998058672A1 (en) 1998-12-30
IL133305A0 (en) 2001-04-30
NO996274D0 (no) 1999-12-17
PT1034001E (pt) 2004-12-31
CZ458899A3 (cs) 2000-04-12
CZ295805B6 (cs) 2005-11-16
KR20010013964A (ko) 2001-02-26
EA200000059A1 (ru) 2000-08-28
HUP0002048A2 (hu) 2000-10-28
HUP0002048A3 (en) 2002-09-30
ES2226152T3 (es) 2005-03-16
BR9810755A (pt) 2000-08-15
EP1034001A1 (en) 2000-09-13
SK180399A3 (en) 2000-06-12
CN1261285A (zh) 2000-07-26
NO996274L (no) 2000-02-18
EE9900587A (et) 2000-08-15
EA002512B1 (ru) 2002-06-27
DE69825473D1 (de) 2004-09-09
BG104092A (en) 2000-10-31
IS5274A (is) 1999-11-26

Similar Documents

Publication Publication Date Title
HK1031825A1 (en) Cd154 blockade therapy for therapeutic protein inhibitor syndrome.
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
WO2001021259A3 (en) Use and compositions for treating platelet-related disorders using anagrelide
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
AU2002360592A1 (en) Inhibitors of hepatitis c virus
GR3035971T3 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents.
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
MY114347A (en) Synergistic therapeutic compositions and methods.
WO2002085405A3 (en) COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
HK1064950A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
NO984760L (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
WO2000041508A3 (en) Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
WO2003099212A3 (en) Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
EP1009421A4 (en) PROCESS AND COMPOSITIONS FOR IMPROVED Wounds Healing
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
IL136225A0 (en) Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
UA94022C2 (ru) Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
WO2004017902A3 (en) Ubiquitin and ubiquitin related molecules for treatment and prevention of harmful activation of the immune system
IL124870A0 (en) Nitric oxide (no) synthase inhibitor to treat or prevent type ii diabetes
WO2001074341A3 (en) Composition for treating allergic and inflammatory conditions with cough containing a non-sedating histamine and an expectorant

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE NAME AND ADDRESS OF PROPRIETOR FROM BIOGEN IDEC MA, INC, 14 CAMBRIDGE CENTER, CAMBRIDGE, MASSACHUSETTS 02142, UNITED STATES/UNITED STATES OF AMERICA TO BIOGEN IDEC MA INC., 14 CAMBRIDGE CENTER, CAMBRIDGE, MA 02142, UNITED STATES/UNITED STATES OF AMERICA.

Effective date: 20060331

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090619